Immunotherapy: From Advanced NSCLC to Early Stages, an Evolving Concept

Thierry Berghmans*, Valerie Durieux, Lizza E. L. Hendriks, Anne-Marie Dingemans

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

Original languageEnglish
Article number90
Number of pages16
JournalFrontiers in medicine
Volume7
DOIs
Publication statusPublished - 24 Mar 2020

Keywords

  • non-small cell lung cancer
  • pembrolizumab
  • atezolizumab
  • nivolumab
  • immunotherapy
  • checkpoint inhibition
  • CELL LUNG-CANCER
  • QUALITY-OF-LIFE
  • IMMUNE-CHECKPOINT INHIBITORS
  • OPEN-LABEL
  • 1ST-LINE TREATMENT
  • NEOADJUVANT CHEMOTHERAPY
  • ANTI-PD-1 ANTIBODY
  • COST-EFFECTIVENESS
  • NIVOLUMAB
  • PEMBROLIZUMAB

Cite this